Kamradt et al. 23 reported a minimal region of alteration of ∼1.7 Mb in prostate cancers that spanned two candidate genes—IL11-RA and DCTN3. Recently, 9p13 DNA gain has been reported for oral tumors 42,43. This evidence concerns the gene DCTN3 and prostate cancer.